Y-mAbs Therapeutics, Inc.(YMAB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

YMAB Y-mAbs Therapeutics, Inc.

Halted 09-15 16:00:00 EDT

8.61

+0.00

0.00%

High8.61	Low8.61	Vol0.00
Open8.61	D1 Closing8.61	Amplitude0.00%
Mkt Cap391.22M	Tradable Cap160.07M	Total Shares45.44M
T/O6.54M	T/O Rate0.00%	Tradable Shares18.59M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"YMAB","market":"US","secType":"STK","nameCN":"Y-mAbs Therapeutics, Inc.","latestPrice":8.61,"timestamp":1757966400000,"preClose":8.61,"halted":3,"volume":0,"delay":0,"floatShares":18591433,"shares":45438420,"eps":-0.494799,"marketStatus":"Halted","change":0,"latestTime":"09-15 16:00:00 EDT","open":8.61,"high":8.61,"low":8.61,"amount":6543391.3619,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.494799,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1537502400000,"exchange":"NASDAQ","adjPreClose":8.61,"volumeRatio":0},"requestUrl":"/m/hq/s/YMAB","defaultTab":"news","newsList":[{"id":"2572535555","title":"HBM Healthcare Investments Reports CHF 236 Million Quarterly Profit, NAV Up 16.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2572535555","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572535555?lang=en_us&edition=fundamental","pubTime":"2025-10-01 23:49","pubTimestamp":1759333787,"startTime":"0","endTime":"0","summary":"Net asset value  per share increased by 16.4% in the second quarter of fiscal year 2025/2026 to CHF 251.78. The company reported a quarterly profit of CHF 236 million, offsetting the currency-related loss from the first quarter. For the first half of the current fiscal year, the company expects a profit of CHF 96 million and an increase in NAV of 6.1% in Swiss francs . The share price rose by 4.0% during the same period and trades at a 28% discount to NAV. The positive second quarter results are mainly attributed to developments in listed portfolio companies, including clinical study results from Abivax, Mineralys, Upstream Bio, and UniQure, as well as acquisition offers for Merus, Y-mAbs Therapeutics, and 89Bio. Foreign currency effects had no material impact on the second quarter's performance. The final half-year results will be published on October 24, 2025.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nNDL5tnLj9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","BK4585","QURE","LU0109394709.USD","LU0889565916.HKD","BK4139","MRUS","UPB","YMAB","ETNB"],"gpt_icon":0},{"id":"2557520774","title":"Y-mAbs Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2557520774","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557520774?lang=en_us&edition=fundamental","pubTime":"2025-08-08 22:10","pubTimestamp":1754662246,"startTime":"0","endTime":"0","summary":"Y-mAbs Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryY-mAbs Therapeutics Inc YMAB.OQ reported a quarterly adjusted loss of 7 cents per share for the quarter ended Ju","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nL8N3U02DX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YMAB"],"gpt_icon":0},{"id":"2557523994","title":"Y-mAbs Therapeutics' Q2 revenue falls 14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557523994","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557523994?lang=en_us&edition=fundamental","pubTime":"2025-08-08 18:44","pubTimestamp":1754649883,"startTime":"0","endTime":"0","summary":"Y-mAbs Therapeutics' Q2 revenue falls 14%OverviewY-mAbs Q2 2025 rev declines 14% yr/yr, adjusted EPS beats expectationsSERB Pharmaceuticals to acquire Y-mAbs for $412 mln, closing by Q4 2025Co's acqui","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nPLX540158:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YMAB"],"gpt_icon":0},{"id":"2557528256","title":"Y-mAbs Therapeutics Q2 EPS $(0.07) Beats $(0.26) Estimate, Sales $19.52M Beat $18.39M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2557528256","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557528256?lang=en_us&edition=fundamental","pubTime":"2025-08-08 18:36","pubTimestamp":1754649372,"startTime":"0","endTime":"0","summary":"Y-mAbs Therapeutics Q2 EPS $(0.07) Beats $(0.26) Estimate, Sales $19.52M Beat $18.39M Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/46993736/y-mabs-therapeutics-q2-eps-0-07-beats-0-26-estimate-sales-19-52m-beat-18-39m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YMAB","LENZ"],"gpt_icon":0},{"id":"2557528250","title":"Y-mAbs Therapeutics Q2 EPS USD -0.07 VS. Ibes Estimate USD -0.27","url":"https://stock-news.laohu8.com/highlight/detail?id=2557528250","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557528250?lang=en_us&edition=fundamental","pubTime":"2025-08-08 18:35","pubTimestamp":1754649300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nPLX540158:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","YMAB"],"gpt_icon":0},{"id":"2557376680","title":"Y-mAbs Therapeutics Inc : Morgan Stanley Raises to Equal-Weight From Underweight; Raises Target Price to $8.6 From $7","url":"https://stock-news.laohu8.com/highlight/detail?id=2557376680","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557376680?lang=en_us&edition=fundamental","pubTime":"2025-08-06 19:15","pubTimestamp":1754478910,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nFWN3TY1PI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["YMAB","BK4139"],"gpt_icon":0},{"id":"2557431296","title":"Y-mAbs Therapeutics Inc. to Be Delisted from Nasdaq Following Acquisition by SERB Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2557431296","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557431296?lang=en_us&edition=fundamental","pubTime":"2025-08-06 05:10","pubTimestamp":1754428218,"startTime":"0","endTime":"0","summary":"Y-mAbs Therapeutics Inc. is set to be delisted from the Nasdaq exchange following its acquisition by SERB Pharmaceuticals. As part of an all-cash transaction, SERB will acquire all outstanding shares of Y-mAbs at $8.60 per share, valuing the company at approximately $412 million. The delisting will occur after the merger is completed, and shareholders who did not tender their shares in the offer will receive the same per-share price. SERB is obligated to commence the tender offer by August 19, 2025, and the delisting will follow the completion of this process.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Y-mAbs Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250805:nNDL3d93nw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YMAB","BK4139"],"gpt_icon":0},{"id":"2557316859","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2557316859","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557316859?lang=en_us&edition=fundamental","pubTime":"2025-08-06 02:03","pubTimestamp":1754416992,"startTime":"0","endTime":"0","summary":"Y-mAbs Therapeutics  shares doubled after the company agreed to be acquired by SERB Pharmaceuticals for $412 million.Intraday volume of Y-mAbs stock topped 16.5 million shares versus the daily average of 208,000.SolarMax Technology  said that its SolarMax Renewable Energy Provider unit signed an engineering, procurement and construction agreement with Longfellow BESS I for a battery storage project in Pecos County, Texas, generating revenue of $127.3 millionThe shares rose 80% as volume topped 303.6 million versus the daily average of 143,000.Xometry  shares advanced 51% after the company reported Q2 non-GAAP earnings and revenue that topped Wall Street estimates.Volume topped 3.49 million versus the daily average of almost 670,000.Price: 8.52, Change: +4.33, Percent Change: +103.34","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4104","BK4096","BK4139","BK4539","BK4561","XMTR","SMXT","YMAB","BK4122"],"gpt_icon":0},{"id":"2557315082","title":"BUZZ-U.S. STOCKS ON THE MOVE-Axon, Cummins, Pfizer","url":"https://stock-news.laohu8.com/highlight/detail?id=2557315082","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557315082?lang=en_us&edition=fundamental","pubTime":"2025-08-06 01:49","pubTimestamp":1754416199,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Axon, Cummins, PfizerEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://refi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250805:nL6N3TX0SG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FIS","TAP","LU2098885051.SGD","PFE","LDOS","ULCC","VRTX","DD","CWD","GFS","BRBR","SMXT","YUM","BK4581","ETN","LU1951198990.SGD","AGL","LU1917777945.USD","CAT","IT","AMAL","ZEPP","AXON","LU1023059063.AUD","YMAB","AWK","SMX","AMRC","LU2517655291.USD","NB","ZBRA","LU2237438978.USD","AYRO","IE00BLSP4452.SGD","IE00B19Z9P08.USD","IE00BZ1G4Q59.USD","LU1852331112.SGD","TDG","HSIC","BK4520","INSP","ICHR","AMGN","CMI","BK4158"],"gpt_icon":1},{"id":"2557315962","title":"JonesTrading Downgrades Y-mAbs Therapeutics to Hold From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2557315962","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557315962?lang=en_us&edition=fundamental","pubTime":"2025-08-06 00:42","pubTimestamp":1754412149,"startTime":"0","endTime":"0","summary":"Y-mAbs Therapeutics (YMAB) has an average rating of overweight and mean price target of $14.78, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["YMAB","LENZ"],"gpt_icon":0},{"id":"2557397665","title":"Dow Surges Over 100 Points; Pfizer Earnings Top Views","url":"https://stock-news.laohu8.com/highlight/detail?id=2557397665","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557397665?lang=en_us&edition=fundamental","pubTime":"2025-08-05 21:59","pubTimestamp":1754402353,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"cf236ffb5b1f701a443d820042ce3a06","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/25/08/46858190/dow-surges-over-100-points-pfizer-earnings-top-views","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCOM","SMXT","AGL","STTK","ICHR","PFE","YMAB","INSP"],"gpt_icon":0},{"id":"2557927683","title":"Serb Pharmaceuticals Agrees To Acquire Y-Mabs Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2557927683","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557927683?lang=en_us&edition=fundamental","pubTime":"2025-08-05 21:42","pubTimestamp":1754401361,"startTime":"0","endTime":"0","summary":"Aug 5 (Reuters) - Y-mAbs Therapeutics Inc ::*SERB PHARMACEUTICALS AGREES TO ACQUIRE Y-MABS THERAPEUTICS*Y-MABS THERAPEUTICS INC: SERB TO COMMENCE ALL-CASH TENDER OFFER TO ACQUIRE ALL OUTSTANDING SHARE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250805:nRSD8T1vwk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YMAB","BK4139"],"gpt_icon":0},{"id":"2557913793","title":"Y-mAbs Therapeutics Inc - Serb Offers $8.60 per Share for Y-mAbs, 105% Premium","url":"https://stock-news.laohu8.com/highlight/detail?id=2557913793","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557913793?lang=en_us&edition=fundamental","pubTime":"2025-08-05 20:30","pubTimestamp":1754397000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250805:nTUA9HVHV7:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["YMAB","BK4139"],"gpt_icon":0},{"id":"2557039134","title":"Y-mAbs Therapeutics Inc: Serb to Commence All-Cash Tender Offer to Acquire All Outstanding Shares of Y-mAbs for $8.60 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2557039134","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557039134?lang=en_us&edition=fundamental","pubTime":"2025-08-05 20:30","pubTimestamp":1754397000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250805:nTUA9HVHV7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["YMAB","BK4139"],"gpt_icon":0},{"id":"2554782789","title":"Y-mAbs Therapeutics Inc. Unveils Presentation on Innovative Oncology Leadership and Therapeutic Platforms","url":"https://stock-news.laohu8.com/highlight/detail?id=2554782789","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554782789?lang=en_us&edition=fundamental","pubTime":"2025-07-25 01:45","pubTimestamp":1753379117,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Y-mAbs Therapeutics Inc. published the original content used to generate this news brief on July 24, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250724:nNDL602PCQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","YMAB"],"gpt_icon":0},{"id":"2551399192","title":"Y-mAbs Therapeutics Inc. Held Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2551399192","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551399192?lang=en_us&edition=fundamental","pubTime":"2025-07-16 04:16","pubTimestamp":1752610579,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Y-mAbs Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 15, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250715:nNDL86hpPF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YMAB","BK4139"],"gpt_icon":0},{"id":"2539125831","title":"Y-mAbs Therapeutics Inc. Unveils Radiopharmaceutical R&D Update, Showcasing Innovative Approaches to Enhance Patient Safety and Treatment Efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=2539125831","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539125831?lang=en_us&edition=fundamental","pubTime":"2025-05-29 17:18","pubTimestamp":1748510318,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Y-mAbs Therapeutics Inc. published the original content used to generate this news brief on May 27, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL6nhkYg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","YMAB"],"gpt_icon":0},{"id":"2538477281","title":"Wedbush Lowers Price Target on Y-mAbs Therapeutics to $18 From $21, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2538477281","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538477281?lang=en_us&edition=fundamental","pubTime":"2025-05-28 23:29","pubTimestamp":1748446188,"startTime":"0","endTime":"0","summary":"Y-mAbs Therapeutics (YMAB) has an average rating of overweight and mean price target of $15.42, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fro","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","YMAB"],"gpt_icon":0},{"id":"2536686079","title":"Y-mAbs Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2536686079","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536686079?lang=en_us&edition=fundamental","pubTime":"2025-05-19 19:46","pubTimestamp":1747655160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/YMAB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 19, 2025 07:46 ET (11:46 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YMAB","LENZ"],"gpt_icon":0},{"id":"2535070328","title":"Y-mAbs Therapeutics Is Maintained at Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2535070328","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535070328?lang=en_us&edition=fundamental","pubTime":"2025-05-15 00:26","pubTimestamp":1747239960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/YMAB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 14, 2025 12:26 ET (16:26 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YMAB","LENZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ymabs.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0.0035},{"period":"6month","weight":0.6338},{"period":"1year","weight":-0.1641},{"period":"ytd","weight":0.0996}],"compareEarnings":[{"period":"1week","weight":0.0034},{"period":"1month","weight":0.012},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1445},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.17}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.012002},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.03065},{"month":3,"riseRate":0.428571,"avgChangeRate":0.050071},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.006181},{"month":5,"riseRate":0.714286,"avgChangeRate":0.132788},{"month":6,"riseRate":0.428571,"avgChangeRate":0.032536},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.042055},{"month":8,"riseRate":0.714286,"avgChangeRate":0.183506},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.043161},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.081791},{"month":11,"riseRate":0.714286,"avgChangeRate":0.029491},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.069815}],"exchange":"NASDAQ","name":"Y-mAbs Therapeutics, Inc.","nameEN":"Y-mAbs Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Y-mAbs Therapeutics, Inc.(YMAB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Y-mAbs Therapeutics, Inc.(YMAB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Y-mAbs Therapeutics, Inc.,YMAB,Y-mAbs Therapeutics, Inc.股票,Y-mAbs Therapeutics, Inc.股票老虎,Y-mAbs Therapeutics, Inc.股票老虎国际,Y-mAbs Therapeutics, Inc.行情,Y-mAbs Therapeutics, Inc.股票行情,Y-mAbs Therapeutics, Inc.股价,Y-mAbs Therapeutics, Inc.股市,Y-mAbs Therapeutics, Inc.股票价格,Y-mAbs Therapeutics, Inc.股票交易,Y-mAbs Therapeutics, Inc.股票购买,Y-mAbs Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Y-mAbs Therapeutics, Inc.(YMAB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Y-mAbs Therapeutics, Inc.(YMAB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction